Ken Griffin Veracyte, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Veracyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,200 shares of VCYT stock, worth $866,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,200

Previous 8,700 166.67%

Holding current value

$866,288

Previous $192,000 161.46%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$18.86 - $23.55 $140,280 - $175,164	-7,438 Reduced 13.5%	47,642 $1.03 Million
Q1 2024 May 15, 2024	SELL	$21.0 - $29.1 $13.6 Million - $18.9 Million	-649,032 Reduced 92.18%	55,080 $1.22 Million
Q4 2023 Feb 14, 2024	SELL	$19.72 - $28.68 $143,344 - $208,474	-7,269 Reduced 1.02%	704,112 $19.4 Million
Q3 2023 Nov 14, 2023	BUY	$22.33 - $29.92 $11.2 Million - $15.1 Million	503,449 Added 242.12%	711,381 $15.9 Million
Q2 2023 Aug 14, 2023	SELL	$20.96 - $26.99 $19.6 Million - $25.2 Million	-934,459 Reduced 81.8%	207,932 $5.3 Million
Q1 2023 May 15, 2023	BUY	$20.58 - $27.89 $12.2 Million - $16.5 Million	591,907 Added 107.52%	1,142,391 $25.5 Million
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $2.21 Million - $4.33 Million	144,559 Added 35.61%	550,484 $13.1 Million
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $2.02 Million - $3.4 Million	121,788 Added 42.86%	405,925 $6.74 Million
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $1.67 Million - $3.18 Million	107,769 Added 61.1%	284,137 $5.66 Million
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $789,181 - $1.53 Million	35,970 Added 25.62%	176,368 $4.86 Million
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $4.18 Million - $6.22 Million	-115,698 Reduced 45.18%	140,398 $5.78 Million
Q3 2021 Nov 15, 2021	BUY	$35.62 - $52.97 $881,844 - $1.31 Million	24,757 Added 10.7%	256,096 $11.9 Million
Q2 2021 Aug 16, 2021	BUY	$32.94 - $56.62 $3.89 Million - $6.69 Million	118,122 Added 104.33%	231,339 $9.25 Million
Q1 2021 May 17, 2021	BUY	$44.47 - $81.38 $4.58 Million - $8.38 Million	103,032 Added 1011.61%	113,217 $6.09 Million
Q4 2020 Feb 16, 2021	SELL	$32.49 - $61.88 $2.82 Million - $5.36 Million	-86,680 Reduced 89.49%	10,185 $498,000
Q3 2020 Nov 16, 2020	BUY	$26.73 - $35.67 $2.59 Million - $3.46 Million	96,865 New	96,865 $3.15 Million
Q2 2020 Aug 14, 2020	SELL	$19.49 - $28.11 $361,929 - $522,002	-18,570 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$16.13 - $30.17 $299,534 - $560,256	18,570 New	18,570 $451,000
Q4 2019 Feb 14, 2020	SELL	$20.78 - $29.99 $1.45 Million - $2.1 Million	-69,922 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$23.87 - $30.93 $308,615 - $399,893	12,929 Added 22.69%	69,922 $1.68 Million
Q2 2019 Aug 14, 2019	SELL	$22.1 - $28.56 $3.38 Million - $4.36 Million	-152,776 Reduced 72.83%	56,993 $1.63 Million
Q1 2019 May 15, 2019	BUY	$12.0 - $25.76 $279,528 - $600,053	23,294 Added 12.49%	209,769 $0
Q4 2018 Feb 14, 2019	BUY	$9.15 - $14.85 $747,866 - $1.21 Million	81,734 Added 78.03%	186,475 $2.35 Million
Q3 2018 Nov 13, 2018	BUY	$9.55 - $12.64 $893,526 - $1.18 Million	93,563 Added 837.03%	104,741 $0
Q1 2018 May 11, 2018	SELL	$5.44 - $6.97 $424 - $543	-78 Reduced 0.69%	11,178 $62,000
Q4 2017 Feb 09, 2018	BUY	$6.05 - $9.37 $68,098 - $105,468	11,256	11,256 $74,000

Others Institutions Holding VCYT

# of Institutions

270

Shares Held

78.7M

Call Options Held

42.3K

Put Options Held

18.2K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.67B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account